Atea Pharmaceuticals is hosting a virtual Hepatitis C virus (HCV) key opinion leader (KOL) panel on May 14, 2025. Experts will discuss challenges faced by HCV patients and results from Atea's Phase 2 study of bemnifosbuvir and ruzasvir. This panel...